48948 Federal Register / Vol. 71, No. 162 / Tuesday, August 22, 2006 / Notices 

The Institute will manufacture small 

quantities of cocaine and marihuana 

derivatives for use by their customers in 

analytical kits, reagents, and reference 

standards as directed by NIDA. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections being sent via regular mail 

should be addressed, in quintuplicate, 

to the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative/ODL; or 

any being sent via express mail should 

be sent to DEA Headquarters, Attention: 

DEA Federal Register Representative/ 

ODL, 2401 Jefferson-Davis Highway, 

Alexandria, Virginia 22301; and must be 

filed no later than October 23, 2006. 

Dated: August 15, 2006. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E6–13841 Filed 8–21–06; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in Schedule I or II and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2)(B) authorizing the importation 

of such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on May 12, 

2006, Wildlife Laboratories, Inc., 1401 

Duff Drive, Suite 400, Fort Collins, 

Colorado 80524, made application to the 

Drug Enforcement Administration 

(DEA) by renewal to be registered as an 

importer of Etorphine Hydrochloride 

(9059), a basic class of controlled 

substance listed in Schedule II. 

The company plans to import the 

listed controlled substance for sale to its 

customers. 

Any manufacturer who is presently, 

or is applying to be, registered with DEA 

to manufacture such basic classes of 

controlled substances may file 

comments or objections to the issuance 

of the proposed registration and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such written comments or 

objections being sent via regular mail 

should be addressed, in quintuplicate, 

to the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative/ODL; or 

any being sent via express mail should 

be sent to DEA Headquarters, Attention: 

DEA Federal Register Representative/ 

ODL, 2401 Jefferson-Davis Highway, 

Alexandria, Virginia 22301; and must be 

filed no later than September 21, 2006. 

This procedure is to be conducted 

simultaneously with and independent 

of the procedures described in 21 CFR 

1301.34(b), (c), (d), (e) and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance listed in 

Schedule I or II are, and will continue 

to be required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a), 21 U.S.C. 823(a), and 21 

CFR 1301.34(b), (c), (d), (e) and (f) are 

satisfied. 

Dated: August 15, 2006. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E6–13842 Filed 8–21–06; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 17, 2006, and 

published in the Federal Register on 

April 21, 2006, (71 FR 20729), Guilford 

Pharmaceuticals, Inc., 6611 Tributary 

Street, Baltimore, MD 21224, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Cocaine (9041), a basic class of 

controlled substance listed in Schedule 

II. 

The company plans to manufacture a 

cocaine derivative to be used in clinical 

research studies. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Guilford Pharmaceuticals, Inc. to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Guilford Pharmaceuticals, 

Inc. to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with State 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: August 15, 2006. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E6–13848 Filed 8–21–06; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Foreign Claims Settlement 

Commission 

Meeting Notice No. 7–06 

The Foreign Claims Settlement 

Commission, pursuant to its regulations 

(45 CFR part 504) and the Government 

in the Sunshine Act (5 U.S.C. 552b), 

hereby gives notice in regard to the 

scheduling of meetings for the 

transaction of Commission business and 

other matters specified, as follows: 

DATE AND TIME: Thursday, August 31, 

2006, at 10 a.m. 

SUBJECT MATTER: Issuance of Proposed 

Decisions and Amended Final Decisions 

in claims against Albania. 

STATUS: Open. 

All meetings are held at the Foreign 

claims Settlement Commission, 600 E 

Street, NW., Washington, DC. Requests 

for information, or advance notices of 

intention to observe an open meeting, 

may be directed to: Administrative 

Officer, Foreign Claims Settlement 

Commission, 600 E Street, NW., Room 

6002, Washington, DC 20579. 

Telephone: (202) 616–6988. 

Dated at Washington, DC. 

Mauricio J. Tamargo, 

Chairman. 

[FR Doc. 06–7103 Filed 8–18–06; 1:36 pm] 

BILLING CODE 4410–01–P 


cprice-sewell on PROD1PC66 with NOTICES